대추추출물및감귤류과피추출물을포함하는지질대사개선및혈압강하용조성물

    公开(公告)号:KR100296250B1

    公开(公告)日:2001-10-25

    申请号:KR1019980012818

    申请日:1998-04-10

    Abstract: PURPOSE: A composition containing a jujube extract and a tangerine pericarp extract containing naringin and hesperidin is provided which has an effect on prevention of adult diseases and cancer such as liver diseases, hypertension, arteriosclerosis, hyperlipidemia or the like when administered to animals. CONSTITUTION: This composition comprises a jujube extract and hesperidin, hesperetin, naringin, naringenin or a mixture thereof as flavonoid originated from a tangerine pericarp extract in a weight ratio of 1:0.001 to 1:0.1. For an example, 5kg jujube is extracted with 15L water at 100deg.C for 2hr two times, followed by filtering. The filtrate is then concentrated under reduced pressure to produce 2kg extract. And 500g tangerine is extracted with 5L ethanol at 60deg.C for 5 hr to produce 190g extract. The jujube extract and tangerine pericarp extract can be orally or parenterally administered at a dose of 0.1 to 5g, preferably 0.5 to 1g and 0.1 to 10g, preferably 0.5 to 2g/kg.weight.day respectively.

    네오헤스페리딘디하이드로칼콘을포함하는동맥경화증,고지혈증,간질환,고혈당증의예방및치료용조성물
    2.
    发明公开
    네오헤스페리딘디하이드로칼콘을포함하는동맥경화증,고지혈증,간질환,고혈당증의예방및치료용조성물 失效
    包含NEOHESPERIDIN DIHYDROCHALCONE的组合物,用于预防和治疗高脂血症,肠梗塞,肝病和高血压

    公开(公告)号:KR1020000019720A

    公开(公告)日:2000-04-15

    申请号:KR1019980037963

    申请日:1998-09-15

    Abstract: PURPOSE: A pharmaceutical composition and functional food and drink comprising neohesperid in dihydrochalcone are provided, for treating and preventing hyper lipidemia, arteriosclerosis, a liver disease and hyperglycemia. CONSTITUTION: The pharmaceutical composition comprises neohesperid in dihydrochalcone ineffective amount; and pharmaceutically acceptable carriers. The functional food or drink comprises 0.01-20 wt%, preferably 0.1-5 wt% of neohesperid in dihydrochalcone. Neohesperidin dihydrochalcone reduces the concentration of serum GOT (glutamate-oxaloacetate transaminase), GPT (glutamate-pyruvate transminase) and a lipid in blood, inhibits HMG CoA (3-hydroxy-3-methylglutaryl coenzyme) being a reduction enzyme which relates to the biosynthesis of cholesterol and ACAT (acyl CoA; cholesterol-O-acyltransferase) which transforms cholesterol into cholesteryl ester, and inhibits the damage of a liver cell and the formation of a fatty liver. Also neohesperid in dihydrochalcone strongly inhibits the macrophage-lipid complex from being deposited or adsorbed onto the intra trial surface, and reduces the concentration of blood sugar.

    Abstract translation: 目的:提供一种包含二氢查耳酮中新月皮的药物组合物和功能性食品和饮料,用于治疗和预防高脂血症,动脉硬化,肝脏疾病和高血糖症。 组成:药物组合物含二氢查耳酮中的新皮肤无效量; 和药学上可接受的载体。 功能性食品或饮料包含二氢查耳酮中的新鲜皮肤的0.01-20重量%,优选0.1-5重量%。 新橙皮苷二氢查耳酮降低血清GOT(谷氨酸 - 草酰乙酸转氨酶),GPT(谷氨酸 - 丙酮酸转氨酶)和血液中的脂质的浓度,抑制与生物合成相关的还原酶的HMG CoA(3-羟基-3-甲基戊二酰辅酶) 的胆固醇和ACAT(酰基CoA;胆固醇-O-酰基转移酶),其将胆固醇转化为胆固醇酯,并且抑制肝细胞的损伤和脂肪肝的形成。 二氢查耳酮中的新生皮肤也强烈地抑制巨噬细胞 - 脂质复合物沉积或吸附到试验表面,并降低血糖浓度。

    바이오플라보노이드 화합물을 포함하는 혈당 강하용 조성물
    3.
    发明公开
    바이오플라보노이드 화합물을 포함하는 혈당 강하용 조성물 无效
    包含用于降低血糖的生物素化合物的组合物

    公开(公告)号:KR1020000019716A

    公开(公告)日:2000-04-15

    申请号:KR1019980037958

    申请日:1998-09-15

    CPC classification number: A61K31/34 Y10S514/866

    Abstract: PURPOSE: A pharmaceutical composition and a functional food comprising bioflavonoid compounds are provided, for descending blood sugar. CONSTITUTION: The pharmaceutical composition comprises the bioflavonoid compounds represented by the formula 1 in effective amount; and pharmaceutically acceptable carriers. In the formula 1, R¬1 represents OH, rutinosyl or rhaminosyl group, R¬2 represents H, OH or rutinosyl group, R¬3 represents H or OH group, R¬4 represents OH or method group, and X represents a single bond or a double bond. The functional food comprises 0.01-50 wt%, preferably 0.05-10 wt% of the bioflavonoid compounds. The compounds of the formula 1 descends blood sugar, and therefore can be used for treating or preventing hyperglycemia.

    Abstract translation: 目的:提供包含生物类黄酮化合物的药物组合物和功能性食品,用于降血糖。 构成:药物组合物包含有效量的式1所示的生物类黄酮化合物; 和药学上可接受的载体。 在式1中,R 1表示OH,芸香酰基或脱氨基糖基,R 2表示H,OH或芸香糖基,R 3表示H或OH基,R 4表示OH或方法基,X表示单 债券或双重债券。 功能性食品包含0.01-50重量%,优选0.05-10重量%的生物类黄酮化合物。 式1的化合物降低血糖,因此可用于治疗或预防高血糖症。

    탄닌 또는 탄닌 유래 페놀성 화합물을 포함하는동맥경화증, 고지혈증 및 지방간의 예방 및 치료용 식품조성물
    10.
    发明公开
    탄닌 또는 탄닌 유래 페놀성 화합물을 포함하는동맥경화증, 고지혈증 및 지방간의 예방 및 치료용 식품조성물 无效
    食品复合材料用于预防和治疗阿片样物质,高胆固醇和包括鞣制或鞣制酚醛化合物的肝硬化

    公开(公告)号:KR1020010030556A

    公开(公告)日:2001-04-16

    申请号:KR1020000062335

    申请日:2000-10-23

    Abstract: PURPOSE: Food composites including tannin or tannin-derived phenolics are provided to prevent and treat arteriosclerosis, hyperlipidemia and hepatic steatosis by dosing tannin, gallic acid or/and ellagic acid. CONSTITUTION: Tannin, gallic acid or/and ellagic acid is/are added to a food or a drink to prevent and treat arteriosclerosis. Tannin(C76H52O46) is extracted from acorns, persimmons and walnut shells. Gallic acid(C7H6O5) and ellagic acid(C14H6O8) are the decomposition products of tannin and have anticancer activities. The amount of the tannin-derived phenolics is from 0.01wt.% to 20wt.% according to the weight, age, gender, health status, diet, dosage time and method, excretory rate and disease level of patients.

    Abstract translation: 目的:提供包括单宁或单宁衍生物酚类的食品复合材料,以预防和治疗单宁,没食子酸或鞣花酸的动脉硬化,高脂血症和肝脂肪变性。 构成:将单宁,没食子酸或/和鞣花酸加入到食物或饮料中以预防和治疗动脉硬化。 单宁(C76H52O46)从橡子,柿子和核桃壳中提取。 没食子酸(C7H6O5)和鞣花酸(C14H6O8)是单宁的分解产物,具有抗癌活性。 根据体重,年龄,性别,健康状况,饮食,剂量时间和方法,患者的排泄率和病情水平,单宁衍生物酚类的含量为0.01重量%〜20重量%。

Patent Agency Ranking